Amicus Therapeutics, Inc. - FOLD Total Company Value-to-Revenue Ratio

Public company logo of Amicus Therapeutics, Inc. (FOLD)

The EV/Revenue multiple for Amicus Therapeutics (FOLD) reflects current market sentiment, with the 7408.71 mark indicating the current state. Business growth is constrained by the number of patients with rare genetic pathologies and FDA decisions. The orphan drug status of the medications ensures high margins and a stable cash flow. However, geopolitical fragmentation and sanctions complicate international logistics and scientific research.

FOLD Amicus Therapeutics: Enterprise Value-to-Revenue Ratio in the range 11/23/2025 - 05/09/2026

FOLD (Amicus Corp): analytical breakdowns and indicator data

Fundamental company valuation:FOLD (Amicus Therapeutics)
Mass-produced product of Amicus Pharma

For Amicus Therapeutics (FOLD), this indicator reflects the enterprise value of the business, accounting for net debt, relative to the volume of generated sales. By analyzing the current enterprise value-to-revenue ratio, an investor can assess how effectively the scaling of Pompe disease therapy justifies the company's capitalization, where an increasing multiple signals expectations for the accelerated commercial rollout of the drug.

Competitor analysis for Amicus Therapeutics

ASND: Enterprise Value-to-Revenue Ratio|MDGL: EV/Sales Multiple|CORT - Total Company Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio Rhythm Corp|Akero Corp (AKRO) - Total Company Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio metsera.com (MTSR)|Company Value to Revenue moonlaketx.com MLTX|EV/Sales Multiple CRNX (Crinetics Pharmaceuticals, Inc.)|NAMS: Company Value to Revenue Ratio|SLNO - Enterprise Value-to-Revenue Ratio|ETNB: Enterprise Value-to-Revenue Ratio|AGIO: EV/Sales Multiple|Structure Therapeutics Inc. - Business Value to Revenue|MDXG (MiMedx Corp) - EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Rezolute Inc RZLT|EV/Sales Multiple LXRX|Total Company Value-to-Revenue Ratio MBX Corp|Altimmune Pharma - Company Value to Revenue|EV/Sales Multiple aardvarktherapeutics.com AARD|SGMT: Company Value to Revenue|Business Value to Revenue BIOA (BioAge Labs)|BMEA: EV/Sales Multiple|QNCX: Enterprise Value-to-Revenue Coefficient|GUTS (Fractyl Health, Inc.) - EV/Sales Multiple|EV/Sales Multiple vtvtherapeutics.com|Company Value to Revenue ATPC (Agape ATP Corp)|Total Company Value-to-Revenue Ratio Pluristem Therapeutics|Enterprise Value-to-Revenue Ratio synlogictx.com SYBX|LPCN: Company Value to Revenue Ratio|MTNB - Enterprise Value-to-Revenue Ratio|Spruce Biosciences, Inc. (SPRB) - Company Value to Revenue|GLTO: EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Carmell Corp. (CTCX)|LUMO (Lumos Therapeutics) - EV/Sales Multiple|Organovo Corp (ONVO) - Total Company Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio Radius Recycling (RDUS)